Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × tafasitamab × Lymphoid × Clear all

Phase

Phase 2 18 Phase 1/2 8 Phase 1 4 Phase 3 3 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 24 Etoposide 15 Rituximab 14 Cytarabine 13 Vincristine 12 Methotrexate 12 Prednisone 10 Doxorubicin 10 Dexamethasone 10 Radiotherapy 8 Filgrastim 7 Mercaptopurine 6 Daunorubicin 6 Asparaginase 6 pegaspargase 5 fludarabine 5 Granulocyte Colony-Stimulating Factor 5 Drug Therapy 5 Dasatinib 5 blinatumomab 4 Methylprednisolone 4 Busulfan 4 venetoclax 3 ruxolitinib 3 prednylidene 3 fludarabine phosphate 3 etoposide phosphate 3 deltacortene 3 Trimethoprim, Sulfamethoxazole Drug Combination 3 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02763319 2025-07-17

B-MIND

Incyte Corporation

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡